Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

ACON

Aclarion Inc

Oct 11 • 04:00PM ET

0.1762

Dollar change -0.0068
Percentage change -3.72	%

Healthcare • Health Information Services • USA • NASD

Peers: ABT AXGN CUTR GEHC HOLX IRIX LUMO OSUR SRTS TRIB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.00	Insider Own	5.17%	Shs Outstand	10.04M	Perf Week	2.56%
Market Cap	1.77M	Forward P/E	-	EPS next Y	-0.55	Insider Trans	0.00%	Shs Float	9.53M	Perf Month	-9.64%
Income	-5.90M	PEG	-	EPS next Q	-0.17	Inst Own	3.28%	Short Float	2.74%	Perf Quarter	-39.74%
Sales	0.05M	P/S	35.38	EPS this Y	90.14%	Inst Trans	17.86%	Short Ratio	0.54	Perf Half Y	-43.35%
Book/sh	0.20	P/B	0.88	EPS next Y	37.36%	ROA	-231.70%	Short Interest	0.26M	Perf Year	-97.25%
Cash/sh	0.12	P/C	1.50	EPS next 5Y	-	ROE	-714.18%	52W Range	0.16 - 9.90	Perf YTD	-94.49%
Dividend Est.	-	P/FCF	-	EPS past 5Y	4.93%	ROI	-359.31%	52W High	-98.22%	Beta	0.42
Dividend TTM	-	Quick Ratio	1.23	Sales past 5Y	32.45%	Gross Margin	-373.56%	52W Low	10.19%	ATR (14)	0.01
Dividend Ex-Date	-	Current Ratio	1.23	EPS Y/Y TTM	60.68%	Oper. Margin	-8711.11%	RSI (14)	42.32	Volatility	5.07% 6.14%
Employees	4	Debt/Eq	0.48	Sales Y/Y TTM	-35.23%	Profit Margin	-10937.65%	Recom	1.00	Target Price	1.25
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	94.67%	Payout	-	Rel Volume	0.23	Prev Close	0.18
Sales Surprise	0.00%	EPS Surprise	0.00%	Sales Q/Q	-35.74%	Earnings	Aug 23	Avg Volume	480.02K	Price	0.18
SMA20	-0.84%	SMA50	-15.20%	SMA200	-75.91%	Trades		Volume	112,432	Change	-3.72%

Oct-10-24 07:00AM	Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-27-24 06:57AM	Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes (GlobeNewswire)
Sep-13-24 08:30AM	PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology (GlobeNewswire)
Sep-12-24 06:57AM	Aclarion Provides Corporate Update on Nociscan AI Technology Milestones (GlobeNewswire) +15.38%
06:00AM	Transforming Oncology: Stocks to Watch in the Oncology Sector (News Direct)
01:00PM	Loading…
Sep-11-24 01:00PM	Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing (ACCESSWIRE)
06:00AM	Aclarion, Inc.'s (NASDAQ: ACON) Emerging Role in the Back Pain Management Sector (News Direct)
Sep-10-24 06:57AM	Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial (GlobeNewswire)
Sep-06-24 11:27AM	Aclarion Added to PRISM Emerging Medical Devices Index (GlobeNewswire)
Sep-05-24 06:57AM	Aclarion Launches Surgeon Partnership to Apply Nociscan's AI Technology to Personal Injury and Workers Compensation Market (GlobeNewswire) -6.49%
Aug-29-24 06:57AM	Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey (GlobeNewswire) -5.20%
Aug-21-24 07:57AM	Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans (GlobeNewswire)
Aug-15-24 09:48AM	Aclarion to Present at August 20th Virtual Investor Summit Microcap Event (GlobeNewswire) +10.48%
Aug-14-24 08:08AM	Aclarion Announces First Commercial Agreement in Michigan (GlobeNewswire) -10.27%
Aug-13-24 09:07AM	Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK (GlobeNewswire) -16.98%
07:00AM	Loading…
Jul-09-24 07:00AM	Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK (GlobeNewswire)
Jun-26-24 08:30AM	Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK (GlobeNewswire) +6.34%
Jun-25-24 08:30AM	Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London (GlobeNewswire)
Jun-20-24 08:00AM	Aclarion Receives Notice of Allowance for US Patent to Support Further Optimization of Accuracy and Reliability in the Nociscan Solution (NewMediaWire)
Jun-18-24 07:00AM	Aclarion Announces Updated Product Release That Enhances User-Experience, Scalability, and Security for Nociscan Solution (NewMediaWire)
May-15-24 10:55PM	ACON Stock Earnings: Aclarion Reported Results for Q1 2024 (InvestorPlace) +17.99%
Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE) -11.57%
Apr-25-24 09:14AM	Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain (GlobeNewswire) +36.35%
Apr-23-24 08:00AM	Aclarion to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024 (NewMediaWire)
Mar-04-24 08:00AM	Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs (GlobeNewswire) +10.18%
Feb-27-24 03:22PM	Aclarion Announces Closing of $3.0 Million Public Offering (GlobeNewswire)
Feb-26-24 09:15AM	Aclarion Announces Pricing of $3.0 Million Public Offering (GlobeNewswire) -60.59%
08:42AM	Why Is Aclarion (ACON) Stock Down 19% Today? (InvestorPlace)
Feb-05-24 08:00AM	Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership (GlobeNewswire)
Jan-29-24 09:31AM	Thinking about buying stock in Spectral AI, Applied UV, Adobe, BigBear.ai, or Aclarion? (PR Newswire) -11.97%
09:17AM	Loading…
09:17AM	Why Is Aclarion (ACON) Stock Down 16% Today? (InvestorPlace)
Jan-26-24 07:58AM	Why Is Aclarion (ACON) Stock Up 109% Today? (InvestorPlace) +52.28%
Jan-22-24 08:00AM	Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD (GlobeNewswire) -7.12%
Jan-17-24 08:00AM	Aclarion Announces Updated Product Release That Expands MRI Scanner Access for Nociscan Solution (GlobeNewswire) +5.70%
Jan-08-24 08:00AM	Aclarion and ATEC Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan (GlobeNewswire) +17.65%
Jan-02-24 12:00PM	Aclarion Announces Reverse Stock Split (GlobeNewswire)
Nov-27-23 08:00AM	Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams (GlobeNewswire)
Nov-08-23 08:00AM	Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption (GlobeNewswire) +7.69%
Nov-06-23 08:00AM	Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD (GlobeNewswire)
Nov-01-23 08:00AM	Aclarion Presents at the NIH HEAL Initiative Fall Meeting (GlobeNewswire) -6.90%
Oct-25-23 08:30AM	Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver (GlobeNewswire) +42.86%
Oct-24-23 08:45AM	Aclarion Announces Nociscan Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting (GlobeNewswire) -10.56%
Oct-23-23 07:00AM	Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan (GlobeNewswire) -36.28%
Oct-02-23 08:00AM	Aclarion Provides Updated Investor Presentation and Corporate Update (GlobeNewswire) +25.90%
Aug-25-23 04:10PM	Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report (GlobeNewswire)
Jun-14-23 11:27AM	Aclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MI (GlobeNewswire)
Jun-08-23 07:30AM	Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting (GlobeNewswire) +23.08%
May-30-23 07:30AM	Aclarion Announces New Engagement with The London Clinic and London Spine Clinic (GlobeNewswire) +77.97%
May-23-23 07:30AM	Aclarions Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD (GlobeNewswire) -9.91%
07:00AM	Aclarion, Inc. Announces Delayed 10-Q Filing (GlobeNewswire)
May-19-23 07:30AM	Aclarion Announces Non-Convertible Debt Financing to Achieve Three Critical Catalysts (GlobeNewswire)
May-11-23 12:41PM	Aclarion providing less invasive solution to treat lo back pain through augmented intelligence (News Direct)
May-02-23 07:00AM	Aclarion Appoints Nicholas Theodore, MD as Principal Investigator for CLARITY Post-Market Trial Evaluating Nociscan in the Diagnosis and Treatment of Chronic Low Back Pain (GlobeNewswire) -5.81%
Apr-28-23 11:20AM	Aclarion to Host Thought Leadership Symposium at SPINEWEEK 2023 (GlobeNewswire) -16.17%
Apr-24-23 07:00AM	Aclarion Announces Publication of 2YR Outcomes in Groundbreaking Clinical Trial (GlobeNewswire) +73.00%
Mar-07-23 09:19AM	Aclarion Announces Alpesh Patel MD MBA as a Key Opinion Leader Physician Advisor (GlobeNewswire)
Feb-16-23 07:00AM	Aclarion to Present at Third Annual Winter Wonderland - Best Ideas Virtual Investor Conference on February 21st - 24th, 2023 (ACCESSWIRE)
Feb-15-23 07:00AM	Aclarion Supports Thought Leadership at the 2nd Annual Sonntag Spine Symposium (GlobeNewswire) -6.04%
Feb-05-23 08:50AM	Insiders who bought stock earlier this year lose -US$213k as Aclarion, Inc. (NASDAQ:ACON) drops to US$4.7m (Simply Wall St.)
Jan-31-23 10:01AM	Gregory Basil MD to Join Aclarion as a Key Opinion Leader Surgeon Advisor (GlobeNewswire)
Jan-17-23 08:29AM	Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor (GlobeNewswire) +8.04%
08:00AM	Aclarion to Present at the Jan 26th Virtual Investor Summit Microcap Event (Newsfile)
Dec-22-22 10:36AM	Dr. Christopher Ames to Join Aclarion as a Key Opinion Leader Surgeon Advisor (GlobeNewswire) -8.80%
Dec-21-22 10:23AM	Aclarions Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD (GlobeNewswire)
Dec-19-22 08:33AM	Aclarion Adds to Growing Key Opinion Leader Program with Juan Uribe M.D. as a Surgeon Advisor (GlobeNewswire) -13.03%
Dec-01-22 09:41AM	Aclarion Adds to Strong Patent Portfolio with Notice of Allowance for New U.S. Patent Application Addressing Key Pain Indicator Biomarker (GlobeNewswire) +9.03%
Nov-16-22 05:12AM	Aclarion Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.) -8.91%
Oct-25-22 07:00AM	Aclarion, Inc. Releases Updated Investor Presentation In Connection with Appearance at LD Micro Main Event XV (ACCESSWIRE) +8.96%
Oct-24-22 07:00AM	Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor (ACCESSWIRE)
Oct-12-22 07:00AM	Aclarion To Present at The LD Micro Main Event XV (Newsfile)
Oct-10-22 07:05AM	Aclarion Announces Participation at the NASS 37th Annual Meeting (ACCESSWIRE) +8.73%
Oct-03-22 07:03AM	John Keller M.D. to Join Aclarion as a Key Opinion Leader Surgeon Advisor (ACCESSWIRE) +9.91%
Sep-19-22 07:03AM	Nociscan Selected for Inclusion in Pivotal National Institutes of Health (NIH) Study for Low Back Pain (ACCESSWIRE) -8.93%
Aug-04-22 07:00AM	Aclarion, Inc. to Present at Investor Summit Group's Q3 Virtual Conference (Newsfile)
Jul-22-22 09:01AM	Quite a few insiders invested in Aclarion, Inc. (NASDAQ:ACON) last year which is positive news for shareholders (Simply Wall St.)
Jul-20-22 07:00AM	Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan (ACCESSWIRE)
Jun-22-22 07:00AM	Aclarion to Present 2-year Follow Up Data on Pivotal Clinical Trial Linking Nociscan to Better Surgical Outcomes for Discogenic Low Back Pain (ACCESSWIRE)
Apr-26-22 09:15PM	Aclarion, Inc. Announces Closing of $9.4 Million Initial Public Offering (ACCESSWIRE)
Apr-21-22 07:45PM	Aclarion, Inc. Announces Listing on Nasdaq and Pricing of $9.4 Million Initial Public Offering (ACCESSWIRE)

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACON

Aclarion Inc

Upgrade your FINVIZ experience